Developed by the International Working Group for the Prognosis of MDS (IWG-PM) under the aegis of the MDS Foundation, Inc.
When entering values into the calculator, note the units given in parentheses. Also note that the usual ranges, given for orientation, are in brackets. These are not normal ranges.
Variables (units) [usual range]
Value
Hemoglobin (g/dL) [4-20]
A possible conversion for Hb values:
10 g/dL= 6.2 mmol/L, 8 g/dL= 5.0 mmol/L
A possible conversion for Hb values:
10 g/dL= 6.2 mmol/L, 8 g/dL= 5.0 mmol/L
Absolute Neutrophil Count (x109/L) [0-15]
Platelets (x109/L) [0-2000]
Bone Marrow Blasts (percent) [0-30]
Cytogenetic Category
Very Good Good
Intermediate
Poor Very Poor
IPSS-R SCORE
IPSS-R CATEGORY
Age-adjusted calculation of risk (IPSS-RA):
(only for survival estimation)
Age
Years
IPSS-R SCORE
(including age)
(including age)
IPSS-R CATEGORY
(including age)
(including age)
IPSS-R Cytogenetic risk groups*,**
| Cytogenetic prognostic subgroups | Cytogenetic abnormalities |
| Very good | -Y, del(11q) |
| Good | Normal, del(5q), del(12p), del(20q), double including del(5q) |
| Intermediate | del(7q), +8, +19, i(17q), any other single or double independent clones |
| Poor | -7, inv(3)/t(3q)/del(3q), double including -7/del(7q), Complex: 3 abnormalities |
| Very poor | Complex: >3 abnormalities |
IPSS-R Prognostic Score Values*
| Prognostic variable | 0 | 0.5 | 1 | 1.5 | 2 | 3 | 4 |
| Cytogenetics | Very Good | Good | Intermediate | Poor | Very Poor | ||
| BM Blast % | <=2 | >2-<5% | 5-10% | >10% | |||
| Hemoglobin | =>10 | 8-<10 | <8 | ||||
| Platelets | =>100 | 50-<100 | <50 | ||||
| ANC | =>0.8 | <0.8 |
IPSS-R Prognostic Risk Categories/Scores*
| RISK CATEGORY | RISK SCORE |
| Very Low | <=1.5 |
| Low | >1.5 - 3 |
| Intermediate | >3 - 4.5 |
| High | >4.5 - 6 |
| Very High | >6 |
IPSS-R: Prognostic Risk Category Clinical Outcomes*
***Medians, years ^Median time to 25% AML evolution
*Greenberg, Tuechler, Schanz et al, Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome, Blood 120: 2454, 2012.
**Schanz J et al, J Clin Oncology 2012; 30:820
| No. pts | Very Low | Low | Intermediate | High | Very High | |
| Patients (%) | 7012 | 19% | 38% | 20% | 13% | 10% |
| Survival*** | 8.8 | 5.3 | 3.0 | 1.6 | 0.8 | |
| AML/25%***,^ | NR | 10.8 | 3.2 | 1.4 | 0.7 | |
*Greenberg, Tuechler, Schanz et al, Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndrome, Blood 120: 2454, 2012.
**Schanz J et al, J Clin Oncology 2012; 30:820
